Nuvation Bio gets FDA Fast Track for safusidenib in glioma
Nuvation Bio says the FDA granted Fast Track designation to safusidenib for treatment of IDH1-mutant glioma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.